34175 Ardenwood Boulevard
96 articles with Ardelyx Inc.
Ardelyx, Inc., announced the appointment of Geoffrey A. Block, M.D., Vice President, Nephrology at Reata and former Director of Clinical Research in the Denver Nephrology Research Division at Colorado Kidney Care/Denver Nephrologists, to the company's board of directors, effective March 14, 2019.
Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
Ardelyx's investigative agent for end-stage renal disease patients on dialysis represents first non-binder innovation to lower patients' phosphate levels, a critically important parameter that is correlated with morbidity and mortality
Company is poised for two Phase 3 readouts in 2H 2019 for tenapanor in hyperphosphatemia
Ardelyx, Inc. announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:30 p.m. ET on Thursday, Feb. 28, 2019 at the Lotte New York Palace Hotel in New York City.
Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
Company Narrows Timeline for its PHREEDOM trial and announces AMPLIFY, a new Phase 3 Trial evaluating tenapanor in combination with binders
Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C
Ardelyx Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).
Tenapanor Second Registration Trial for Hyperphosphatemia Ongoing; On-Track for Data in 2019
Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
Ardelyx, Inc. (Nasdaq: ARDX), today announced the presentation of preclinical data suggesting therapeutic synergy of tenapanor in combination with sevelamer, the current standard-of-care phosphate binder treatment for hyperphosphatemia, or elevated serum phosphorus.
Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
Ardelyx, Inc. (Nasdaq: ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with constipation (IBS-C), the T3MPO-3 trial, were presented this weekend at the American College of Gastroenterology (ACG) 2018 Annual Meeting.
Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an investor event called "Renal Day" on Thursday, Oct. 11, 2018, from 8 to 10 a.m. ET in New York City.
Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
Tenapanor is a minimally-systemic small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium transporter NHE3 and reduce sodium uptake from the gut.
Operating Runway Extended to Mid-2020
Ardelyx, Inc. announced that it plans to report its second quarter 2018 financial results after market close on Tuesday, August 7, 2018. Management will host a conference call and webcast that afternoon at 4:30 p.m. ET to discuss the results and other business updates.
Ardelyx Inc. (Nasdaq: ARDX), today announced that it has commenced an underwritten public offering of up to $50,000,000 of shares of its common stock.
Knight Therapeutics announced a license agreement with Ardelyx Inc. that provides Knight with exclusive rights to commercialize tenapanor in Canada.
Ardelyx Inc. announced a license agreement with Knight Therapeutics Inc. that provides Knight with exclusive rights to commercialize tenapanor in Canada.
Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors
Ardelyx, Inc. reported pipeline highlights and financial results for the fourth quarter and full-year ended December 31, 2017.
Ardelyx today announced that Jeremy Caldwell, Ph.D., CSO, will be leaving the company, effective February 16, 2018, to pursue a position as chief executive officer of an early stage biotech start-up company based in San Diego.
Ardelyx today announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program, designed to support the registration of tenapanor for the treatment of patients with IBS-C.
The agreement also provides Fosun Pharma the rights to commercialize tenapanor for other indications for which it is approved in the U.S.